{
  "docId": "019de075-4071-7657-953a-43c246cbe714",
  "docSlug": "684835678957e07d55af9fc01c6da54e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 44,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a grid layout to present clinical trial assets on the left and corporate KPIs on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4071-7657-953a-43c246cbe714/30",
  "deckHref": "/decks/019de075-4071-7657-953a-43c246cbe714",
  "deckJsonHref": "/decks/019de075-4071-7657-953a-43c246cbe714.json",
  "deckAnchorHref": "/decks/019de075-4071-7657-953a-43c246cbe714#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Confident in leading growth profile: base business strength with innovative late-stage pipeline",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51f12a97-8dc6-4e17-acfd-d4252356df71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Clinical trial catalysts for capivasertib, Fasenra, Dato-DXd, Imfinzi, and AZD3152",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b304525-b41b-49ec-9f2a-29e28d83b3a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "Corporate ambitions: Revenue growth, margin expansion, 15 NMEs by 2030, and emissions reduction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41896212-dbc4-48ce-bfc9-5921912cf020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Indicates Company ambition to achieve Total Revenue low double-digit CAGR through 2025...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aed94126-a7ce-434c-bc10-d29f12ac4778",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Key trial readouts reinforce transformative pipeline potential",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86bbb265-58e3-4b8c-83d2-0f31694285bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Robust Phase III catalysts in H2 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6f86b79-a77f-4adb-b289-a95d8bdf47f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 32,
      "from": 28,
      "beatId": "5f9b510c-f470-41f6-ba7c-2aef7f47aeaa",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The CEO's closing remarks and the Q&A session encourage action and engagement",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 32,
      "from": 29,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "92eccba8-3f8f-46ae-80bb-464c461b36a0",
      "evidence": "The presentation highlights AstraZeneca's initiatives to address climate change",
      "position": 1,
      "objective": "To emphasize the importance of taking bold action to mitigate climate change",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}